"BioSeeker's ""Basic Platform Report: Apoptosis"" provides a complete and systematic description of the past present and future efforts in cancer R&D, focused on the apoptosis as molecular target. We have, identified, structured and defined information necessary to analyze the cancer drug candidates that aim at targeting the cell death pathway or by disturbing the cell cycle. Overall the basic platform entails close to 100 industry related R&D projects. Thousands of records from a multitude of sources build the structure and content of this report. The report is divided in 6 sections each section structured to enable the study of a specific topic (see below). ""Basic Platform Report: Apoptosis"" is a unique gathering of information found no were else.
Example of companies included:
BioSeeker has identified more than 60 companies with a clear interest of apoptosis and we have listed the biggest players within this field below:
Abbott laboratories, Aegera, Amgen, Antisoma, Apoxis, Aprea AB ArQule, AVI BioPharma, Biomeasure, Bristol-Myers Squibb, Cambridge Antibody Tech, CEREP, Chroma Therapeutics, Cyclacel, Cyclis, De Novo, Eli Lilly and Company, Exelixis, Gemin X Biotechnologies, Genentech, Genta, Hoffmann-La Roche, Human Genome Sciences, Hybridon, Idun Pharmaceuticals, Incyte Genomics, Introgen Therapeutics, ISIS Pharmaceuticals, Kirin Brewery, Maxim Pharmaceuticals, Millennium Pharmaceuticals, Molecular Engines Laboratories, Nano Cure, Novartis, Onyx Pharmaceuticals, Rigel Pharmaceuticals, Sankyo, Sanofi-Aventis, Santaris Pharma, Takeda Chemical Industries, Tanox, Vernalis.
The report will assist you in:
- Tracking cutting edge companies, therapies and new technologies
- Rapid identification of promising drug candidates and future partners & competitors
- Rapid identification of in-licensing opportunities
- Identifying novel apoptosis targeting agents
- Building a comprehensive framework for further analysis of the apoptosis targeting field
- Customizing your own presentation covering the development of cancer apoptosis therapeutics
This + 1000 pages basic platform report is arranged into several major sections to optimize the usability of the report.
This product is a part of Bioseekers Analytical Tool - Apoptosis: Promise or deception?"
|
Section I: Investigators
This section will enable our customers to rapidly study and identify which investigators are active in apoptosis targeting R&D. It will as well assist in studying and build up a complete picture of research activities among the different investigators that are active in this field.
Section II: Drug candidates
This section will assist in studying R&D activities and progress for the different drugs included. It will as well enable a historical description the progress of each drug and structure all collaborative partners involved in R&D for each drug candidate. Section II gives you a possibility to study activities and efforts for each drug in relation to different cancer indications.
Section III: Developmental stage
This section enables you to structure and study the level and progress that each drug candidate has reached. The time frame for a drug to progress from the different developmental phases (pre-clinical up to approved) reflects difficulties and commitment among the investigators.
Section IV: Indications
This section outlines different diseases found by BioSeeker Group. Major cancer indications are also divided into sub-indication categories such as: NSCLC, SCLC, Androgen-Independent, Androgen-dependent, Hormone-Refractory, ALL, AML, CLL, CML, NHL, Stage 1-4, relapsed, recurrent and metastatic cancers. This section assists our customers to study competitors and possible collaborative partners working in the same disease areas.
Section V: Therapeutic types
This section enables you to track down competition among the different therapeutic types under development. Most types of therapeutic strategies have been defined and structured (small molecular drugs, monoclonal antibodies, antisense, anti-idiotypic antibodies, biological drugs, gene therapy, cell therapy, vaccines).
Section VI: Mechanism of action & targets
In this section BioSeeker Group provide an extensive architecture over mechanisms and targets for the different drug candidates. It is divided in two categories, mechanisms and targets. Mechanisms included in this report are: Cell-cycle inhibitors, Cell death pathway interactions and Tumor suppressors. Some of the identified targets are: Aurora kinase, Bcl-2, Bcl-xL, Caspase, Cell cycle checkpoint, Cyclin dependent kinase, Histone deacetylase, Mdm2, p53 Survivin, TRAIL, XIAP etc.
Share this report
Other tasks Related Markets Oncology/Hematology Reports Free Alert Me service Receive bi-weekly email alerts on new market research Sign Up Today!
|
